## **Knobbe Martens Olson & Bear LLP**

Intellectual Property Law

550 West C Street Suite 1200 San Diego CA 92101 Tel 619-235-8550 Fax 619-235-0176 www.kmob.com

# **URGENT**

### FACSIMILE TRANSMITTAL SHEET

#### CONFIRMATION COPY WILL FOLLOW VIA:

	MAIL						WILL <u>NOT</u> FOLLOW
	INTERNATIONAL	L AIRMA	$\mathbf{IL}$		•		HAND DELIVERY
	COURIER						WITH ENCLOSURES
ō	E-MAIL				٠.		WITHOUT ENCLOSURES
_				• •	٠.	:	

#### Confidentiality Notice:

The documents accompanying this facsimile transmission contain confidential information which may be legally privileged. The information is intended only for the use of the recipient named below. If you have received this facsimile in error, please immediately notify us by telephone to arrange for return of the original documents to us; and any disclosure, copying, distribution or the taking of any action in reliance on the contents of this faxed information is strictly prohibited.

To:

Examiner Isis Ghali

FIRM:

**USPTO** 

FACSIMILE NO.:

703-872-9306 571-273-0045

OUR REF.:

LOMAU.143A

APPL. No.:

10/041688

FROM:

Gregory A. Hermanson

**OPERATOR:** 

Connie Nuckels

No. OF PAGES: 2

(incl. cover sheet)

DATE:

January 8, 2007

#### IF YOU DID NOT RECEIVE ALL OF THE PAGES PLEASE CALL BACK IMMEDIATELY

OPERATOR PHONE No.: (619) 235-8550

FACSIMILE No.: (619) 235-0176

#### **MESSAGE:**

PLEASE FIND AN INTERVIEW REQUEST FORM ATTACHED IN ANTICIPATION OF THE SCHEDULED INTERVIEW TOMORROW, JANUARY 9, 2007, AT 2:30 PM EST (11:30 AM PST). PLEASE CONTACT US IF YOU HAVE ANY QUESTIONS.

PTOL-413A (09-08)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Application No. 10/041688 First Named Applicant: Zhu, Yong-Hua Examiner: Isis Ghali Art Unit: 1615 Status of Application: Pending  Tentative Participants: (I) Examiner Isis Ghali (2) Rose M. Theisen  (3) Gregory Hermanson (4)  Proposed Date of Interview: January 9, 2007 Proposed Time: 11:30am PST Type of Interview Requested: (I)   Telephonic (2) [ ] Personal (3) [ ] Video Conference  Exhibit To Be Shown or Demonstrated: [ ] YES	Applicant Initiated Interview Request Form											
(1) Examiner Isis Ghali (2) Rose M. Theissen  (3) Gregory Hermanson (4)  Proposed Date of Interview: January 9, 2007 Proposed Time: 11:30mm PST Type of Interview Requested: (1)   Yesperior (3)   Video Conference  Exhibit To Be Shown or Demonstrated:   YES   X  NO  If yes, provide brief description:  Issues To Be Discussed  Issues Claims/ Discussed Agreed Not Agreed (Rel, Obj., etc) Fig. #s Prior Art (1) Reg. 1,2 WO '374; '352 [] [] []  (2) [] [] [] []  (3) [] [] [] []  (4) [] Continuation Sheet Attached  Rrief Description of Arguments to be Presented: 352 distloses encapsulating a pH modifier, but does not teach or disclose, e.g., "microcapsule comprising a protective shell that blocks undesired reactions by substantially preventing direct contact of the antibiotic and the cyonoacrylate," as claimed An interview was conducted on the above-identified application on NOTE: This form should be completed by applicant and submitted to the examiner in advance of the interview (see MPEP § 713.01). This application will not be delayed from issue because of applicant's failure to submit a written record of this interview. Therefore, applicant is advised to file a statement of the substance of this interview (37 CFR 1.133(b)) as soon as soosible.  Application of Applicant or Representative Signature  Gregory A. Hermanson Typed/Printed Name of Applicant or Representative 53.018	Application No.: 10/041688 First Named Applicant: Zhu, Yong-Hua  Examiner: Isis Ghali Art Unit: 1615 M Status of Application: Pending											
Proposed Date of Interview: January 9, 2007  Proposed Time: 11:30am PST Type of Interview Requested: (1)   Telephonic   (2)   Personal   (3)   Video Conference  Exhibit To Be Shown or Demonstrated:   YES   X  NO  If yes, provide brief description:    Issues To Be Discussed   X  NO    Issues To Be Discussed   Agreed   Not Agreed	Tentative Participants: (1) Examiner Isis Ghali (2) Rose M. Theissen											
Type of Interview Requested:  (1) [x] Telephonic (2) [] Personal (3) [] Video Conference  Exhibit To Be Shown or Demonstrated: [] YES [X] NO  If yes, provide brief description:     Issues To Be Discussed   Image:	(3) Gregory Hermanson (4)											
Type of Interview Requested: (1)   Telephonic (2)   Personal (3)   Video Conference  Exhibit To Be Shown or Demonstrated:   YES   X  NO If yes, provide brief description:    Issues	rioposcu Date of filter view. Talluar y 21 2002											
Issues To Be Discussed    Issues	Type of Interview Requested:											
Issues (Rej., Obj., etc) Fig. #s Prior Art  (1) Red. 1,2 WO'374; '352 [] [] []  (2) [] []  (3) [] [] [] []  (4) [] Continuation Sheet Attached  Rrief Description of Arguments to be Presented: 352 discloses encapsulating a pH modifier, but does not teach or disclose, e.g., "microcapsule comprising a protective shell that blocks undesired reactions by substantially preventing direct contact of the antibiotic and the cyonoacrylate," as claimed An interview was conducted on the above-identified application on NOTE: This form should be completed by applicant and submitted to the examiner in advance of the interview (see MPEP § 713.01).  This application will not be delayed from issue because of applicant's failure to submit a written record of this interview. Therefore, applicant is advised to file a statement of the substance of this interview (37 CFR 1.133(b)) as soon as soosible.  Applicative Applicant's Representative Signature  Gregory A. Hermanson Typed/Printed Name of Applicant or Representative 53.018	Exhibit To Be Shown or Demonstrated: [ ] YES [X] NO  If yes, provide brief description:											
Rej., Obj., etc)  Fig. #s  Prior  Art  Art    Reg.	Issues To Be Discussed											
(1) Reig. 1,2 WO '374; '352 [] [] []  (2) [] [] [] [] []  (3) [] [] [] [] []  (4) [] Continuation Sheet Attached    Rrief Description of Arguments to be Presented: '352 discloses' encapsulating a pH modifier, but does not teach or disclose, e.g., "microcapsule comprising a protective shell that blocks undesired reactions by substantially preventing direct contact of the antibiotic and the cyonoacrylate," as claimed An interview was conducted on the above-identified application on NOTE: This form should be completed by applicant and submitted to the examiner in advance of the interview (see MPEP § 713.01).  This application will not be delayed from issue because of applicant's failure to submit a written record of this interview. Therefore, applicant is advised to file a statement of the substance of this interview (37 CFR 1.133(b)) as soon as possible.    Applicant/Applicant's Representative Signature   Examiner/SPE Signature			Prior	Discussed	Agreed	Not Agreed						
(3) [] [] [] []  (4) [] Continuation Sheet Attached  Brief Description of Arguments to be Presented: 352 discloses encapsulating a pH modifier, but does not teach or disclose, e.g., "microcapsule comprising a protective shell that blocks undesired reactions by substantially preventing direct contact of the antibiotic and the cyonoacrylate," as claimed An interview was conducted on the above-identified application on NOTE: This form should be completed by applicant and submitted to the examiner in advance of the interview (see MPEP § 713.01).  This application will not be delayed from issue because of applicant's failure to submit a written record of this interview. Therefore, applicant is advised to file a statement of the substance of this interview (37 CFR 1.133(b)) as soon as possible.  Applicant/Applicant's Representative Signature  Gregory A. Hermanson  Typed/Printed Name of Applicant or Representative  53.018	(1) <b>Rej.</b>	1,2	Art WO '374; '352	[]	[]	[]						
[] [] [] []  [] Continuation Sheet Attached    Rrief Description of Arguments to be Presented:   352 discloses encapsulating a pH modifier, but does not teach or disclose, e.g., "microcapsule comprising a protective shell that blocks undesired reactions by substantially preventing direct contact of the antibiotic and the cyonoacrylate," as claimed An interview was conducted on the above-identified application on NOTE: This form should be completed by applicant and submitted to the examiner in advance of the interview (see MPEP § 713.01).  This application will not be delayed from issue because of applicant's failure to submit a written record of this interview. Therefore, applicant is advised to file a statement of the substance of this interview (37 CFR 1.133(b)) as soon as possible.    Application Applicant's Representative Signature   Examiner/SPE Signature	(2)		*	[]	[]	[]						
Brief Description of Arguments to be Presented:  "352 discloses encapsulating a pH modifier, but does not teach or disclose, e.g., "microcapsule comprising a protective shell that blocks undesired reactions by substantially preventing direct contact of the antibiotic and the cyonoacrylate," as claimed An interview was conducted on the above-identified application on NOTE: This form should be completed by applicant and submitted to the examiner in advance of the interview (see MPEP § 713.01).  This application will not be delayed from issue because of applicant's failure to submit a written record of this interview. Therefore, applicant is advised to file a statement of the substance of this interview (37 CFR 1.133(b)) as soon as fossible.  Applicant/Applicant's Representative Signature  Gregory A. Hermanson  Typed/Printed Name of Applicant or Representative  53.018	(3)			[]	[]	[]						
blocks undesired reactions by substantially preventing direct  contact of the antibiotic and the cyonoacrylate," as claimed  An interview was conducted on the above-identified application on  NOTE: This form should be completed by applicant and submitted to the examiner in advance of the interview (see MPEP § 713.01).  This application will not be delayed from issue because of applicant's failure to submit a written record of this interview. Therefore, applicant is advised to file a statement of the substance of this interview (37 CFR 1.133(b)) as soon as possible.  Applicant/Applicant's Representative Signature  Gregory A. Hermanson  Typed/Printed Name of Applicant or Representative  53.018	(4)	et Attached		[]	[]	[ ]						
Contact of the antibiotic and the cyonoacrylate," as claimed An interview was conducted on the above-identified application on  NOTE: This form should be completed by applicant and submitted to the examiner in advance of the interview (see MPEP § 713.01).  This application will not be delayed from issue because of applicant's failure to submit a written record of this interview. Therefore, applicant is advised to file a statement of the substance of this interview (37 CFR 1.133(b)) as soon as possible.  Applicant/Applicant's Representative Signature  Gregory A. Hermanson  Typed/Printed Name of Applicant or Representative  53.018	Brief Description of Arguments to be Presented:											
An interview was conducted on the above-identified application of NOTE: This form should be completed by applicant and submitted to the examiner in advance of the interview (see MPEP § 713.01).  This application will not be delayed from issue because of applicant's failure to submit a written record of this interview. Therefore, applicant is advised to file a statement of the substance of this interview (37 CFR 1.133(b)) as soon as possible.  Applicant/Applicant's Representative Signature  Gregory A. Hermanson  Typed/Printed Name of Applicant or Representative  53.018	blocks undesired reactions by substantially preventing direct											
This application will not be delayed from issue because of applicant's failure to submit a written record of this interview. Therefore, applicant is advised to file a statement of the substance of this interview (37 CFR 1.133(b)) as soon as possible.  Applicant/Applicant's Representative Signature  Gregory A. Hermanson  Typed/Printed Name of Applicant or Representative  53.018	An interview was conducted on the above-identified application on											
Applicant/Applicant's Representative Signature  Gregory A. Hermanson Typed/Printed Name of Applicant or Representative  53.018	This configuration will not be deleved from issue because of applicant's failure to submit a written record of this											
Gregory A. Hermanson Typed/Printed Name of Applicant or Representative 53.018												
Gregory A. Hermanson Typed/Printed Name of Applicant or Representative 53.018	Applicative Representative Signature Examiner/SPE Signature											
53.018	Gregory A. Hermanson											
	53.018											

This collection of information is required by 37 CFR 1.133. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 21 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.